[go: up one dir, main page]

UA110918C2 - Інгібітори протеїнфосфатази-1 та їх застосування - Google Patents

Інгібітори протеїнфосфатази-1 та їх застосування

Info

Publication number
UA110918C2
UA110918C2 UAA201013424A UAA201013424A UA110918C2 UA 110918 C2 UA110918 C2 UA 110918C2 UA A201013424 A UAA201013424 A UA A201013424A UA A201013424 A UAA201013424 A UA A201013424A UA 110918 C2 UA110918 C2 UA 110918C2
Authority
UA
Ukraine
Prior art keywords
inhibitors
protein phosphatase
hiv
infections
replication
Prior art date
Application number
UAA201013424A
Other languages
English (en)
Inventor
Сергей НЕХАЙ
Дмитро Борисович Ковальський
Original Assignee
Ховард Юніверсіті
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ховард Юніверсіті filed Critical Ховард Юніверсіті
Publication of UA110918C2 publication Critical patent/UA110918C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Було показано, що інгібітори протеїнфосфатази-1 уповільнюють реплікацію ВІЛ-1, Описуються інгібітори ПФ-1 і їх застосування в лікуванні або попередженні інфекцій ВІЛ-1.
UAA201013424A 2008-04-16 2009-04-14 Інгібітори протеїнфосфатази-1 та їх застосування UA110918C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4556108P 2008-04-16 2008-04-16
PCT/US2009/040495 WO2009129224A1 (en) 2008-04-16 2009-04-14 Inhibitors of protein phosphatase-1 and uses thereof

Publications (1)

Publication Number Publication Date
UA110918C2 true UA110918C2 (uk) 2016-03-10

Family

ID=41199444

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201013424A UA110918C2 (uk) 2008-04-16 2009-04-14 Інгібітори протеїнфосфатази-1 та їх застосування

Country Status (7)

Country Link
US (1) US8278326B2 (uk)
EP (1) EP2265117B1 (uk)
AU (1) AU2009236303B2 (uk)
CA (1) CA2721203C (uk)
RU (1) RU2527561C2 (uk)
UA (1) UA110918C2 (uk)
WO (1) WO2009129224A1 (uk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881967C (en) * 2012-08-14 2021-02-23 Howard University Inhibitors of protein phosphatase-1 and uses thereof
WO2022132918A1 (en) * 2020-12-16 2022-06-23 Howard University Method for treating or inhibiting cytomegalovirus infection using small molecules targeting protein phosphatase 1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS61106636A (ja) * 1984-10-31 1986-05-24 Toray Silicone Co Ltd シリコ−ンゴムスポンジ組成物
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5175172A (en) * 1988-12-19 1992-12-29 Francois Dietlin Method of alleviating AIDS symptoms and compositions therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4444045C2 (de) * 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
JP2008528573A (ja) * 2005-01-27 2008-07-31 アルマ マテル ストゥディオルム−ウニヴェルシタ ディ ボローニャ アルツハイマー病の処置に有用な有機化合物、それらの使用及び調製の方法
RU2326115C2 (ru) * 2005-11-21 2008-06-10 Ефаг АО Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения

Also Published As

Publication number Publication date
EP2265117A4 (en) 2012-03-21
CA2721203C (en) 2016-11-01
CA2721203A1 (en) 2009-10-22
EP2265117B1 (en) 2017-06-07
EP2265117A1 (en) 2010-12-29
AU2009236303B2 (en) 2014-12-04
US20090264463A1 (en) 2009-10-22
RU2010146147A (ru) 2012-05-27
RU2527561C2 (ru) 2014-09-10
AU2009236303A1 (en) 2009-10-22
WO2009129224A1 (en) 2009-10-22
US8278326B2 (en) 2012-10-02

Similar Documents

Publication Publication Date Title
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
EA201001372A1 (ru) Формы рифаксимина и их применение
CR20120266A (es) Inmunoglobinas con dominio variable dual y usos de las mismas
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EA200901490A1 (ru) Химические соединения
CY1116509T1 (el) Θεραπευτικος συνδυασμος που περιλαμβανει ντολουτεγκραβιρη, αβακαβιρη και λαμιβουδινη
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
MX2013001362A (es) Inmunoglubinas de dominio variable doble y usos de las mismas.
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
RS53467B (en) USE OF AMISULPRID FOR TREATMENT OF Nausea and Vomiting Caused by Chemotherapy
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
MX2008016453A (es) Composiciones y metodos para tratar infecciones parasitas.
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
NO20092637L (no) Fremgangsmater for behandling
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA200870019A1 (ru) Лактамовые соединения и способы их применения